DN |
Diabetic nephropathy |
ESRD |
End-stage renal disease |
ACE |
Angiotensin converting enzyme |
ARBs |
Angiotensin II receptor blockers |
LPA |
Lysophosphatidic acid |
ATX |
Autotaxin |
AGE |
Advanced glycation end (product) |
GPAT |
Glycerol-3-phosphate acyltransferase |
PLA1 and PLA2 |
Phospholipases A1 or A2 |
PA |
Phosphatidic acid |
LPE |
Lysophosphatidylethanolamine |
LPC |
Lysophosphatidylcholine |
LPS |
Lysophosphatidylserine |
LPPs |
Lipid phosphate phosphatases |
MAG |
Monoacylglycerol |
AGPAT |
Acylglycerophosphate acyltransferase |
PLC |
Phospholipase C |
DAG |
Diacylglycerol |
MAPK |
Mitogen-activated protein kinase |
PI3K |
Phosphatidylinositol 3 kinase |
PKB |
Protein kinase B |
ROCK |
Rho-associated protein kinase |
RAGE |
Receptor for advanced glycation end products |
Nox |
NADPH oxidase |
PPARγ |
Peroxisome proliferator-activated receptor γ |
CKD |
Chronic kidney disease |
ECM |
Extracellular matrix |
GBM |
Glomerular basement membrane |
EMT |
Epithelial mesenchymal transition |
CCL2/MCP1 |
Monocyte chemoattractant protein 1 |
CCL5/RANTES |
Regulated upon activation, normal T cell expressed, and secreted |
ICAM-1 |
Intercellular adhesion molecule-1 |
VCAM-1 |
Vascular cell adhesion molecule-1 |
PAI-1 |
Plasminogen activator inhibitor-1 |
uPA and tPA |
Urokinase-type and tissue-type plasminogen activator |
TIMP-1 |
Tissue inhibitor matrix metalloproteinase-1 |
JNK |
c-Jun N-terminal kinases |
VEGF |
Vascular endothelial growth factor |
SGLT-2 |
Sodium–glucose cotransporter-2 |
GSK3β |
Glycogen synthase kinase 3β |
SREBP 1 |
Sterol regulatory element-binding protein1 |
TGF-β |
Transforming growth factor-β |
TLR 4 |
Toll-like receptor 4 |
NF-KB |
Nuclear factor-KB |
KLF5 |
Krüppel-like factor 5 |
Egr1 |
Early growth response 1 |
S1PR |
Sphingosine 1 phosphate receptor |
GPR4 |
pH-sensing G protein-coupled receptor |
OGR1/GPR68 |
Ovarian cancer G-protein coupled receptor-1 |